Disease Activity at 52 Weeks (ITT population)

Slides:

Advertisements

Similar presentations

IL-6 Inhibition in RA An Emerging Role for Tocilizumab HIGHLIGHTS FROM EULAR 2008 PRESENTATIONS.

Advertisements

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Remission in Established RA Patients

Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.

Achieving remission in early RA Dubai, United Arab Emirates 19. January 2009 Professor Joachim Kalden Friedrich-Alexander University Erlangen-Nuremberg.

Yusuf Yazıcı, MD NYU Hospital for Joint Diseases, New York

WEEK 1 You have 10 seconds to name…

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums Geraldine Navarro, MD, Sara Taroumian, MD, Nashla Barroso,

A NEW LOOK AT RA Interactive Hot Topics Series

A NEW LOOK AT RA Interactive Hot Topics Series

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Disease Activity Assessment Across the RA Continuum

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Percentage of patients achieving DAS28 (CRP) < 3

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

What's New in Therapeutic Options for Moderate to Severe RA?

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

MTX-PG concentrations and hepatotoxicity.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.

Measurement of structure (disease) modification in osteoarthritis

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentage of patients with RA achieving DAS28(CRP)<2

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

Bland and Altman plots showing the JSN progression score difference (y axis) against the mean JSN progression scores (x axis) of the two reading methods.

DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

Treatment Advances for RA

DAPSA LSM change from baseline (A), patients achieving DAPSA ≤28 (MDA) (B), DAPSA ≤14 (LDA) (C) or DAPSA ≤4 (REM) (D) after 24 weeks in patients treated.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Multivariable model of adjusted

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.

Presentation transcript:

Disease Activity at 52 Weeks (ITT population) ACR50 ACR70 Low disease activity DAS28 remission (<2.6) TCZ 4 mg/kg 29% 16% 45% 30% TCZ 8 mg/kg 36% 20% 64% 47% Placebo 10% 4% 19% 8%

Total Sharp-Genant score Joint space narrowing score Radiographic Progression at 52 Weeks (ITT population) Total Sharp-Genant score Erosion score Joint space narrowing score TCZ 4 mg/kg 0.34 0.21 0.13 TCZ 8 mg/kg 0.29 0.17 0.12 Placebo 1.13 0.71 0.42

Week 24: Overall ITT Population ACR20 ACR50 ACR70 EULAR response (Good/moderate) DAS28 remission TCZ 69.9% 44.1% 28% 40.2%/42% 33.6% MTX 52.5% 33.5% 15.1% 16.9%/47.9% 12.1%